CL2016002940A1 - Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo - Google Patents

Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo

Info

Publication number
CL2016002940A1
CL2016002940A1 CL2016002940A CL2016002940A CL2016002940A1 CL 2016002940 A1 CL2016002940 A1 CL 2016002940A1 CL 2016002940 A CL2016002940 A CL 2016002940A CL 2016002940 A CL2016002940 A CL 2016002940A CL 2016002940 A1 CL2016002940 A1 CL 2016002940A1
Authority
CL
Chile
Prior art keywords
pharmaceutically acceptable
amide
carotenoid derivative
acceptable salt
ester
Prior art date
Application number
CL2016002940A
Other languages
English (en)
Inventor
Takashi Fujita
Satoshi Kobayashi
Ryoma Shinohara
Yasuhiro Nishida
Jiro Takahashi
Original Assignee
Fuji Chem Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Chem Ind Co Ltd filed Critical Fuji Chem Ind Co Ltd
Publication of CL2016002940A1 publication Critical patent/CL2016002940A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2016002940A 2014-05-20 2016-11-18 Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo CL2016002940A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014104480 2014-05-20
JP2014247549 2014-12-08

Publications (1)

Publication Number Publication Date
CL2016002940A1 true CL2016002940A1 (es) 2017-09-01

Family

ID=54554071

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002940A CL2016002940A1 (es) 2014-05-20 2016-11-18 Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo

Country Status (18)

Country Link
US (1) US10125104B2 (es)
EP (1) EP3147279A4 (es)
JP (1) JP6393754B2 (es)
KR (1) KR101963946B1 (es)
CN (1) CN106458881B (es)
AU (1) AU2015262405B2 (es)
CA (1) CA2948605C (es)
CL (1) CL2016002940A1 (es)
HK (1) HK1231459A1 (es)
IL (1) IL248700B (es)
MX (1) MX363918B (es)
NZ (1) NZ726535A (es)
PH (1) PH12016502303B1 (es)
RU (1) RU2693455C2 (es)
SG (1) SG11201609405VA (es)
TW (1) TWI654171B (es)
WO (1) WO2015178404A1 (es)
ZA (1) ZA201607968B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461696B (zh) * 2015-12-08 2017-11-24 李秋菊 一种用于脑梗塞康复的药物组合物
JP2021008404A (ja) * 2017-09-27 2021-01-28 アスタファーマシューティカルズ株式会社 変形性関節症改善剤
JP2021028295A (ja) * 2017-11-27 2021-02-25 アスタファーマシューティカルズ株式会社 光学活性のトランス−アスタキサンチン誘導体又はその塩、及びそれらの化合物を含有する組成物
JP2021028300A (ja) * 2017-12-04 2021-02-25 アスタファーマシューティカルズ株式会社 掻痒抑制剤
JP2021028301A (ja) * 2017-12-04 2021-02-25 アスタファーマシューティカルズ株式会社 皮膚炎治療剤
JP2021054718A (ja) * 2018-01-09 2021-04-08 アスタファーマシューティカルズ株式会社 ドライアイ改善剤
WO2019159868A1 (ja) 2018-02-13 2019-08-22 アスタファーマシューティカルズ株式会社 大腸炎改善剤
AU2019282691A1 (en) 2018-06-05 2020-12-24 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
JP2021176821A (ja) * 2018-08-01 2021-11-11 アスタファーマシューティカルズ株式会社 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類
US12338209B2 (en) * 2019-09-27 2025-06-24 Cardax, Inc. Astaxanthin esters and methods of use thereof
WO2022140580A1 (en) 2020-12-24 2022-06-30 Orn Almarsson Xanthophyll derivatives
CN117865853A (zh) * 2023-11-24 2024-04-12 迪嘉药业集团股份有限公司 一种普瑞巴林杂质的制备方法
CN118084755B (zh) * 2024-04-22 2024-08-02 潍坊富邦药业有限公司 一种高水溶性虾青素衍生物及制备方法
CN118063368B (zh) * 2024-04-22 2024-08-02 潍坊富邦药业有限公司 一种水溶性虾青素衍生物及其合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX247604B (es) 2002-02-06 2007-07-30 Dsm Ip Assets Bv Esteres de astaxantina.
US20080008798A1 (en) 2002-02-06 2008-01-10 Arnold Gloor Salts of astaxathin esters
JP4410675B2 (ja) 2002-04-30 2010-02-03 サントリーホールディングス株式会社 アスタキサンチン中鎖脂肪酸エステル、その製造法、およびそれらを含有する組成物
US20050009788A1 (en) 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059659A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050049248A1 (en) 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
EP2392562B1 (en) * 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050004235A1 (en) 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20060234333A1 (en) * 2003-01-09 2006-10-19 Basf Aktiengesellschaft Patents, Trademarks And Licenses Method for producing carotenoids or their precursors using genetically modified organisms of the blakeslea genus, carotenoids or their precursors produced by said method and use thereof
EP1750723A1 (en) 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
CA2610502A1 (en) * 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EP1890729A2 (en) * 2005-05-02 2008-02-27 Cardax Pharmaceuticals, Inc. Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
JP2007176814A (ja) * 2005-12-27 2007-07-12 Yoshihiro Futamura 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤
US20090099061A1 (en) 2006-01-27 2009-04-16 Foss Bente J Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics
JP2007238564A (ja) 2006-03-10 2007-09-20 Fujifilm Corp カロチノイド−コラーゲンペプチド縮合体
WO2008023283A2 (en) 2006-08-25 2008-02-28 Omnica Gmbh Stabilized esters of lutein
EP1952845A1 (en) 2007-01-26 2008-08-06 DSMIP Assets B.V. Use of an astaxathin derivative for cosmetic purposes
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
WO2008118862A1 (en) * 2007-03-23 2008-10-02 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives for the prevention of platelet aggregation
CL2008002577A1 (es) 2007-08-31 2009-10-23 Basf Se Procedimiento para preparar una solucion de un derivado de astaxantina en un aceite comestible que comprende suspender el derivado de astaxantina en aceite comestible cuyo diametro de particulas es de 0,5-50 um, donde el derivado de astaxantina comprende al menos un 70% en peso de al menos un compuesto de la formula (i).
CN102341004B (zh) 2009-03-05 2014-04-16 巴斯夫欧洲公司 虾青素衍生物的粉状组合物i
WO2010100232A2 (de) 2009-03-05 2010-09-10 Basf Se Formulierung von astaxanthin-derivaten und deren verwendung iii
DK2403354T3 (da) 2009-03-05 2013-04-08 Basf Se Formulering af astaxanthin-derivater og anvendelse heraf
DK2403364T3 (da) 2009-03-05 2013-04-29 Basf Se Fremgangsmåde til fremstilling af opløsninger af astaxanthin-derivater
ES2400223T3 (es) 2009-03-05 2013-04-08 Basf Se Formulación de derivados de astaxantina y su utilización II
DK2403362T3 (da) 2009-03-05 2013-04-15 Basf Se Pulverformede sammensætninger af astaxanthin-derivater II
TWI501946B (zh) 2010-02-08 2015-10-01 Basf Se 蝦紅素二琥珀酸二甲酯之製造方法
RU2017112051A (ru) 2014-09-11 2018-10-11 Басф Се Способ получения сложных эфиров астаксантина

Also Published As

Publication number Publication date
MX363918B (es) 2019-04-05
HK1231459A1 (zh) 2017-12-22
KR101963946B1 (ko) 2019-03-29
CA2948605A1 (en) 2015-11-26
NZ726535A (en) 2019-02-22
RU2693455C2 (ru) 2019-07-03
AU2015262405B2 (en) 2019-01-03
RU2016149777A (ru) 2018-06-21
EP3147279A4 (en) 2018-01-10
PH12016502303A1 (en) 2017-02-13
PH12016502303B1 (en) 2019-09-13
JP6393754B2 (ja) 2018-09-19
ZA201607968B (en) 2018-05-30
TWI654171B (zh) 2019-03-21
WO2015178404A1 (ja) 2015-11-26
IL248700A0 (en) 2017-01-31
US10125104B2 (en) 2018-11-13
MX2016015236A (es) 2017-02-23
KR20170007304A (ko) 2017-01-18
EP3147279A1 (en) 2017-03-29
CA2948605C (en) 2019-12-24
RU2016149777A3 (es) 2018-12-28
SG11201609405VA (en) 2016-12-29
CN106458881A (zh) 2017-02-22
TW201625521A (zh) 2016-07-16
US20170081289A1 (en) 2017-03-23
AU2015262405A1 (en) 2016-12-08
CN106458881B (zh) 2019-07-30
IL248700B (en) 2019-06-30
JPWO2015178404A1 (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
CL2016002940A1 (es) Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo
LT3139982T (lt) Rūkinis purkštuvas
EP3140503C0 (en) INITIATOR HEAD ARRANGEMENT
HRP20190431T1 (hr) Anti-her2 antitijelo-lijek konjugat
LT3218504T (lt) Trijų segmentų arenavirusai kaip vakcinos vektoriai
MA40254A (fr) Polymorphes du selinexor
ZA201704602B (en) Dihydroindolizinone derivative
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
IL249356A0 (en) A derivative of 2-acylaminothiazole or a salt thereof
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
DK3143018T3 (da) Carboxamidderivater
DK3107689T3 (da) Dysehoved
EP3463221A4 (en) REVERSIBLE HYSTEROSCOPIC STERILIZATION
IL248772A0 (en) A consequence of cyclohexyl pyridine
HUE042119T2 (hu) Aminoészter-származékok
ZA201807559B (en) Novel prostaglandin derivative
EP3217965C0 (en) Pharmaceutical processing
PL3228650T3 (pl) Nowa pochodna PEG
FR3026520B1 (fr) Processus d'enregistrement de tracabilite
DK3903774T3 (da) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
TH1501004330A (th) อนุพันธ์อะโซลเบนซีน
TH1601003444B (th) องค์ประกอบทางเภสัชกรรมของแคโรทีนอยด์
UA32622S (uk) Пістолет для герметику
ES1133530Y (es) Chupete perfeccionado
UA29132S (uk) Балон для лікарських засобів